Stay updated on Nivolumab Plus Ipilimumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in NSCLC Clinical Trial page.

Latest updates to the Nivolumab Plus Ipilimumab in NSCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page shows a minor revision update from v3.4.1 to v3.4.2, with no visible changes to study content or eligibility details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check19 days agoChange DetectedRevision: v3.4.1 updated from v3.4.0; no user-facing study details or functionality appear to have changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check40 days agoChange DetectedMinor metadata update: Revision v3.3.4 was added and the previous Revision v3.3.3 was removed; this does not affect study content or user-facing details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check69 days agoChange DetectedAdded Location sections listing sites in Arkansas, Connecticut, Florida, Georgia, Missouri, New York, Ohio, South Carolina, Tennessee, Hainaut (Belgium), and Cluj (Romania); removed the previous location blocks, and updated the revision to v3.3.3.SummaryDifference1.0%

- Check90 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2; this change does not affect study details or user-facing content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check98 days agoChange DetectedThe funding/operational status notice was removed from the page; the page now displays the study details without that alert.SummaryDifference0.3%

Stay in the know with updates to Nivolumab Plus Ipilimumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in NSCLC Clinical Trial page.